Abilify — Class III drug recall D-0467-2024
Ongoing recall by Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd., reported 2024-05-01, distributed nationwide. Cross Contamination with Other Products
| Recall number | D-0467-2024 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd., Tokushima, N/A, Japan |
| Recall initiated | 2024-04-09 |
| Classified | 2024-04-23 |
| Reported by FDA | 2024-05-01 |
| Distributed | Nationwide (US) |
| NDC | 59148-0006, 59148-0006-13, 59148-0006-92, 59148-0007, 59148-0007-13, 59148-0007-35, 59148-0007-94, 59148-0008, 59148-0008-13, 59148-0008-35, 59148-0008-95, 59148-0009, 59148-0009-13, 59148-0009-35, 59148-0009-95, 59148-0010, 59148-0010-13, 59148-0010-35, 59148-0011, 59148-0011-13, 59148-0011-35 |
| Expiration dates | 2024-11-30, 2025-04-30, 2025-11-30 |
Product
Abilify (aripiprazole), 10 mg tablets, packaged in a) 30 count bottles (NDC 59148-008-13) and b) 7 count blister packs (NDC 59148-008-95), RX only, Otsuka America Pharmaceutical, Inc.
Reason for recall
Cross Contamination with Other Products
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0467-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.